# The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

> **NCT02220088** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 79 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TAI of FOLFOX
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02220088
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** protocol violation
- **Last updated:** 2019-01-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220088, "The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02220088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*